Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020)
Protagonist Therapeutics (PTGX) reported Deferred Taxes of $34000.0 for Q4 2020, down 95.6% on a YoY basis from $773000.0 in Q1 2020, and up 525.0% sequentially from -$8000.0 in Q3 2020.
Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020) Analysis & Trends
Protagonist Therapeutics (PTGX) has 2 years of Deferred Taxes data on file, last reported at $34000.0 in Q4 2020.
- For the quarter ending Q4 2020, Deferred Taxes fell 95.6% year-over-year to $34000.0; the trailing twelve-month figure through Dec 2020 stood at $1.4 million (up 285.55% YoY), and the FY2020 full-year result was $1.4 million, up 285.55% from the prior year.
- Deferred Taxes climbed to $34000.0 in Q4 2020, from -$8000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $1.2 million in Q2 2020 to a low of -$1.6 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -859,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 34,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 1.23 Mn |
| Mar 31, 2020 | 183,000.00 |
| Dec 31, 2019 | 773,000.00 |
| Sep 30, 2019 | -102,000.00 |
| Jun 30, 2019 | -1.63 Mn |
| Mar 31, 2019 | 180,000.00 |